News Releases

Nov 01, 2024
Biodesix Announces Third Quarter 2024 Results and Highlights
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc.
Oct 29, 2024
Biodesix to Participate in Three Investor Conferences in November
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor
Oct 18, 2024
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
LOUISVILLE, Colo. --(BUSINESS WIRE)--Oct. 18, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday,
Sep 05, 2024
Biodesix to Present at Two Investor Conferences in September
LOUISVILLE, Colo. --(BUSINESS WIRE)--Sep. 5, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team will present at two upcoming investor conferences: Lake Street Capital Markets 8 th
Aug 07, 2024
Biodesix Announces Second Quarter 2024 Results and Highlights
Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million ; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million ; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and
Aug 06, 2024
Biodesix to Present at Canaccord Genuity’s 44th Annual Growth Conference
LOUISVILLE, Colo. --(BUSINESS WIRE)--Aug. 6, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will present in a fireside chat and host in-person 1x1 investor meetings
Jun 18, 2024
Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”
Awarding Excellence in Company Culture LOUISVILLE, Colo. --(BUSINESS WIRE)--Jun. 18, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive,
May 28, 2024
Biodesix to Participate in Two Investor Conferences in June
LOUISVILLE, Colo. --(BUSINESS WIRE)--May 28, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth
Displaying 1 - 10 of 20